While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...
A study supported the ellipsoid zone loss as a meaningful biomarker that can be used to guide clinical trial design in ...
Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video from the American Academy of Ophthalmology meeting, Jennifer I. Lim, MD, MBA, discusses ...
Randomized trials of two FDA-approved intravitreal complement inhibitor injections showed that they slowed the progression of geographic atrophy, but failed to demonstrate functional benefits at 24 ...
SIGLEC Phase 2b data support AVD-104 as a potential therapy to reduce GA lesion growth, preserve and improve visual acuity, and reduce conversion to neovascular AMD across all GA lesion types at 1 ...
Vitamin supplements known to potentially slow the progression of intermediate age-related macular degeneration do not seem to have a similar effect on geographic atrophy, an advanced form of the dry ...
Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback